Showing 1 - 10 of 174
innovation policy in the context of EU economic law (competition policy, intellectual property law, sector regulation). As such … law that moves beyond apparent conflicts and assumes innovation as the starting point. Taking this as the foundation, the … analytical grid to be used to identify ways in which economic law impacts innovation, and second an applied component that …
Persistent link: https://www.econbiz.de/10009205060
This paper addresses the relationship between patent protection and investment in the development of new pharmaceutical … Trade Organization, has increased levels of patent protection around the world. Since patents also have the potential to … patent laws and the severity of disease, we test the hypothesis that increased patent protection results in greater drug …
Persistent link: https://www.econbiz.de/10009002387
the hypothesis that innovation in pharmaceuticals is becoming more difficult and expensive over time, as costs of …This paper quantifies the relationship between market size and innovation in the pharmaceutical industry. We estimate … the elasticity of innovation, as measured by the number of new chemical entities appearing on the market for a given …
Persistent link: https://www.econbiz.de/10009003149
Based on a survey of the inventors of 9,017 European patented inventions, this paper provides new information about the characteristics of European inventors, the sources of their knowledge, the importance of formal and informal collaborations, the motivations to invent, and the actual use and...
Persistent link: https://www.econbiz.de/10005124480
measure of innovation alternative to patent count. Unlike the impact on patent count, we do not find that VC investment … impact on patent count at industry level, and this impact is larger than that of R&D expenditures. We confirm that this … and material. Therefore, our finding suggests that, at industry level, VC investment increases the patent propensity but …
Persistent link: https://www.econbiz.de/10005136420
We develop a theory of innovation for entry and sale into oligopoly, and show that an invention of higher quality is …
Persistent link: https://www.econbiz.de/10008865973
report cross-country comparisons that: (i) focus on 11 therapeutic classes experiencing patent expiration and loss of …
Persistent link: https://www.econbiz.de/10011083891
creating an internal market for pharmaceuticals can be analysed. In a model of third-degree price discrimination, arbitrage … Market in pharmaceuticals are ambiguous, since a movement from segmented and price-controlled markets towards integrated …
Persistent link: https://www.econbiz.de/10005114350
Preventives are sold ex ante, before disease status is realized, while treatments are sold ex post. Even if the mean of the ex ante distribution of consumer values is the same as that ex post, the shape of the distributions may differ, generating a difference between the surplus each product can...
Persistent link: https://www.econbiz.de/10011196028
We provide a method allowing to identify margins in an oligopoly price competition game when prices may not be freely chosen in some markets, for example due to regulation. We use our identification strategy to study the effects of regulatory constraints in the pharmaceutical industry, which is...
Persistent link: https://www.econbiz.de/10011083879